Nxera Pharma Co (TSE:4565) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4565 Nxera Pharma Co Ltd TSE:4565
76 GF Score
Price 円1,299.00
GF Value 円1,221.47
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Nxera Pharma Co Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nxera Pharma Co  (TSE:4565) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nxera Pharma Co Cyclically Adjusted PB Ratio Related Terms


Nxera Pharma Co Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Cyclically Adjusted PB Ratio Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nxera Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 1.57 1.23 1.30 1.47

TSE:4565 vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PB Ratio falls into.


TSE:4565
76GF Score
Nxera Pharma Co Ltd TSE:4565
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nxera Pharma Co's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Nxera Pharma Co's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=709.192/113.6000*113.6000
=709.192

Current CPI (Jun. 2026) = 113.6000.

Nxera Pharma Co Quarterly Data

Book Value per Share CPI Adj_Book
201512 443.564 98.100 513.648
201603 345.129 97.900 400.477
201606 433.893 98.100 502.449
201609 395.992 98.000 459.027
201612 449.772 98.400 519.249
201703 426.293 98.100 493.648
201803 99.200 0.000
201806 609.671 99.200 698.172
201809 597.956 99.900 679.958
201812 544.941 99.700 620.916
201903 571.280 99.700 650.927
201906 542.318 99.800 617.308
201909 551.009 100.100 625.321
201912 584.875 100.500 661.112
202003 547.569 100.300 620.178
202006 529.814 99.900 602.471
202009 598.495 99.900 680.571
202012 649.921 99.300 743.515
202103 680.651 99.900 773.994
202106 685.116 99.500 782.203
202109 659.645 100.100 748.608
202112 704.972 100.100 800.048
202203 693.787 101.100 779.567
202206 688.036 101.800 767.789
202209 679.919 103.100 749.164
202212 707.201 104.100 771.739
202303 710.594 104.400 773.213
202306 761.048 105.200 821.816
202309 703.868 106.200 752.913
202312 746.927 106.800 794.484
202403 736.604 107.200 780.580
202406 767.283 108.200 805.576
202409 753.717 108.900 786.247
202412 762.150 110.700 782.116
202503 746.054 111.100 762.842
202506 727.788 111.700 740.168
202509 725.523 112.000 735.888
202512 674.039 113.000 677.618
202603 703.754 112.700 709.374
202606 709.192 113.600 709.192

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Nxera Pharma Co (TSE:4565) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued. The current stock price of 円1,299.00 is trading 6.3% above its estimated GF Value™ of 円1,221.47. GuruFocus considers Nxera Pharma Co to be Fairly Valued.

Key valuation signals for TSE:4565:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: 円1,221.47 vs. price of 円1,299.00 (6.3% above fair value)
  • GF Score™: 76/100 with 9 warning signs

No single metric tells the full story. See the TSE:4565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
76GF Score

Get the complete analysis for TSE:4565

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,299.00
Price
円1,221.47
GF Value